[go: up one dir, main page]

AR025455A1 - MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES - Google Patents

MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES

Info

Publication number
AR025455A1
AR025455A1 ARP000104536A ARP000104536A AR025455A1 AR 025455 A1 AR025455 A1 AR 025455A1 AR P000104536 A ARP000104536 A AR P000104536A AR P000104536 A ARP000104536 A AR P000104536A AR 025455 A1 AR025455 A1 AR 025455A1
Authority
AR
Argentina
Prior art keywords
contraception
mesoprogestines
conceptives
components
female
Prior art date
Application number
ARP000104536A
Other languages
Spanish (es)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR025455A1 publication Critical patent/AR025455A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de mesoprogestinas para producir un producto farmacéutico para la anticoncepcion femenina, a una preparacion farmacéutica para la anticoncepcionfemenina y a un método anticonceptivo femenino que administra cantidades efectivas de unamesoprogesti na en una mujer que desea contar con anticoncepcion.Opcionalmente, la mesoprogestina puede utilizarse en combinacion con un estrogeno. Las mesoprogestinas se definen como compuestos que disponen de actividadtanto agonística comoantagonística en el r eceptor de progesterona (RP) in vivo. Estabilizan la funcion de RP en un nivel intermedio entre agonístico yantagonístico. Con las progestinas o las antiprogestinas no es posible lograr estados funcionales correspondientes.J867, J912, J956 y J1042 s on lasmesoprogestinas preferibles de acuerdo con la presente.Use of mesoprogestins to produce a pharmaceutical product for female contraception, a pharmaceutical preparation for contraception, and a female contraceptive method that administers effective amounts of unamesoprogestin in a woman who wishes to have contraception.Optionally, mesoprogestin can be used in combination with an estrogen Mesoprogestins are defined as compounds that have agonistic activity as antagonistic in the progesterone receptor (RP) in vivo. They stabilize the RP function at an intermediate level between yantagonistic agonistic. With the progestins or the antiprogestins it is not possible to achieve corresponding functional states.

ARP000104536A 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES AR025455A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
AR025455A1 true AR025455A1 (en) 2002-11-27

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104536A AR025455A1 (en) 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1525215T3 (en) * 2002-08-02 2007-01-15 Schering Ag Modulators for the progesterone receptor with elevated anti-gonadotropic activity for women's fertility control and hormone replacement therapy
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
WO2004098517A2 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
EP1773344A1 (en) * 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
HRP20161437T1 (en) * 2009-04-14 2017-02-10 Laboratoire Hra Pharma Method for on-demand contraception
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
AU630334B2 (en) * 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4332283A1 (en) 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE4447714C2 (en) 1994-08-09 1998-02-05 Jenapharm Gmbh Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd.
ZA959008B (en) * 1994-10-24 1996-09-16 Schering Ag Competitive progesterone antagonists for demand-oriented female birth control
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
ATE213947T1 (en) * 1996-06-25 2002-03-15 Akzo Nobel Nv PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
BR0013711A (en) 2002-05-07
BG106441A (en) 2002-09-30
NO20020998L (en) 2002-03-14
WO2001026603A3 (en) 2002-01-17
LV12940B (en) 2003-06-20
CZ2002707A3 (en) 2002-11-13
AU781835B2 (en) 2005-06-16
WO2001026603A2 (en) 2001-04-19
JP2003511399A (en) 2003-03-25
PL353994A1 (en) 2003-12-15
EP1605949A2 (en) 2005-12-21
PE20010579A1 (en) 2001-06-04
CA2383650A1 (en) 2001-04-19
YU13902A (en) 2006-01-16
KR20020038745A (en) 2002-05-23
NO20020998D0 (en) 2002-02-28
CN1384748A (en) 2002-12-11
CO5190694A1 (en) 2002-08-29
NZ517470A (en) 2004-03-26
MXPA02002186A (en) 2002-09-02
SI20853A (en) 2002-10-31
LT5001B (en) 2003-03-25
AU3215001A (en) 2001-04-23
SK2982002A3 (en) 2002-07-02
HRP20020265A2 (en) 2004-02-29
UA77150C2 (en) 2006-11-15
HUP0202515A2 (en) 2002-12-28
LT2002035A (en) 2002-10-25
EE200200103A (en) 2003-04-15
HUP0202515A3 (en) 2004-06-28
EA200200284A1 (en) 2002-10-31
IL148415A0 (en) 2002-09-12
EA006805B1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
CA2256365A1 (en) Compositions, methods and devices for the transdermal delivery of drugs
PT836506E (en) TRANSDERMAL PENSION FOR ADMINISTRATION OF 17-DECACEACY NORGESTIMATE SO OR IN COMBINATION WITH A ESTROGEN
PT87053A (en) METHOD FOR THE PREPARATION OF CONTRACEPTIVE COMPOSITIONS CONTAINING MELETONIN AND METHOD FOR CONDUCTING CONTRACEPTION
PE20051038A1 (en) EXTENDED COMBINATION USE INCLUDING ESTROGENS AND PROGESTINES
EP1260206A3 (en) Pants-type disposable wearing article
NO20024908D0 (en) 8 <beta> -hydrocarbyl-substituted estrogens for use as selective estrogens
AR035904A1 (en) 5- [2-HIDROXI-3-1- (3-TRIFLUOROMETILFENIL) -CICLOPROPIL-PROPIONILAMINO] -FTALIDA AND COMPOUNDS RELATED TO PROGESTERONE RECEPTOR MODULAR ACTIVITY
ATE288744T1 (en) MEDICINAL FORMULATIONS FOR HORMONE REPLACEMENT THERAPY FOR TOPICAL USE ON THE SKIN
ES2162900T3 (en) L-N-MENTOL LIQUID COMPOSITION AND PROCEDURE FOR PREPARATION.
EA200900451A1 (en) METHOD OF OBTAINING COMPOSITION OF ESTRADIOL WITH SLOW-BREAKDOWN (OPTIONS), ESTRADIOL AND CHOLESTEROL MICROSPHERE AND METHOD FOR SIMULTANEOUS CONTRACEPTION AND HORSE SUBSTITUTION
AR025455A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES
EA200100108A1 (en) APPLICATION OF BIOGENAL SULFAMATS OF ESTROGENS FOR HORMONE-SUBSTITUTE THERAPY
AR048722A1 (en) TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED ANTI-CONCEPTIVE REGIMES
BR0214634A (en) Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate
EP1890758B1 (en) Dosage form cap for an applicator
CR10289A (en) "STRATRIENS 9-ALFA-SUBSTITUTED AS SELECTIVE EFFECTIVENESS STROGENS" (DIVISIONAL)
PE20060318A1 (en) FORM OF ADMINISTRATION FOR HORMONAL CONTRACEPTION
CO5200773A1 (en) MESOPROGESTINES (RECEIVER MODULATORS FOR PROGESTERON) AS A COMPONENT OF COMPOSITIONS USED FOR HORMONAL REPLACEMENT THERAPY (HRT)
BR0214334A (en) Method for providing a topical base composition for use in the preparation of a cosmetic composition, resealable cosmetic container, and anhydrous composition
DE10250470A1 (en) Hygiene product for men and boys, absorbs residual urine discharge and other secretions
CN2376280Y (en) Bottle type urine collector
CN2452478Y (en) Bandage for hip
KR970005295A (en) Vaginal tablets containing bamboo salt and mica as active ingredients
Khomasuridze et al. Characteristics of progestin use in pre-menopausal women
ATE546144T1 (en) USE OF ESTRADIOLVALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF DYSF UNCTIONAL UTERINE BLEEDING IN UNIT WITH ORAL CONTRACEPTION

Legal Events

Date Code Title Description
FB Suspension of granting procedure